Natural Capsules
Healthcare
NATCAPSUQ NSE
₹137.78 +2.37 (+1.75%)
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹137.78 −66.33 −32.5% 1Y
Start ₹204.11
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- −4.58%
- Debt to Equity
- 0.93
- EPS (TTM)
- −₹18.67
- Book Value
- ₹168.08
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 0.82
- ROE
- −9.45%
- Dividend Yield
- 0.74%
- EBITDA
- ₹20.00 L
- 52W High
- ₹234.00
- 52W Low
- ₹131.16
- Day Range
- ₹136.00 – ₹139.95
- Volume
- 1,497
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Natural Capsules (this company) | ₹137.78 | — | ₹142 Cr | 0.82 | 0.74% | −9.45% | −4.58% | ₹191 Cr | −₹25 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.66% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
47 Average
Data confidence 93/100
Category scores
- Quality
- 52
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 51
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 14
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 28
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 52
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.98 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- Company has a low return on equity of -2.06% over last 3 years.
- Contingent liabilities of Rs.75.2 Cr.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.3.72 Cr.
- Promoter holding has decreased over last 3 years: -5.65%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 5 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Strong Bearish
Bearish
12
Neutral
5
Bullish
2
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 35.11
- Neutral
- MACD (12,26,9)
- −8.81
- Bearish
- SMA (50)
- 170.06
- Bearish
- SMA (200)
- 159.21
- Bearish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +18.51% |
|---|---|
| 3Y | +3.23% |
| 1Y | +10.65% |
| TTM | +8.84% |
Net profit
| 5Y | Turned to loss |
|---|---|
| 3Y | Turned to loss |
| 1Y | Turned to loss |
| TTM | Loss widened by ₹19.28 Cr |
Operating cash flow
| 5Y | −3.29% |
|---|---|
| 3Y | −13.51% |
| 1Y | −59.26% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −14.28 pp |
|---|---|
| 3Y | −21.12 pp |
| 1Y | −11.18 pp |
| TTM | −8.09 pp |
Revenue by year
| Mar 2018 | ₹55.00 Cr |
|---|---|
| Mar 2019 | ₹60.00 Cr |
| Mar 2020 | ₹62.00 Cr |
| Mar 2021 | ₹80.00 Cr |
| Mar 2022 | ₹135 Cr |
| Mar 2023 | ₹170 Cr |
| Mar 2024 | ₹155 Cr |
| Mar 2025 | ₹169 Cr |
| Mar 2026 | ₹187 Cr |
Net profit by year
| Mar 2018 | ₹1.00 Cr |
|---|---|
| Mar 2019 | ₹2.00 Cr |
| Mar 2020 | ₹1.00 Cr |
| Mar 2021 | ₹7.00 Cr |
| Mar 2022 | ₹14.00 Cr |
| Mar 2023 | ₹18.00 Cr |
| Mar 2024 | ₹6.00 Cr |
| Mar 2025 | ₹1.00 Cr |
| Mar 2026 | −₹25.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.7 | 37.52 | 39.98 | 40.22 | 39.18 | 41.22 | 43.83 | 44.97 | 45.2 | 45.8 | 37.75 | 58.45 | 48.71 |
| Expenses | 31.74 | 32.4 | 35.26 | 36.11 | 34.81 | 36.72 | 39.56 | 40.58 | 44.88 | 46.69 | 40.07 | 57.12 | 47.59 |
| Operating Profit | 5.96 | 5.12 | 4.72 | 4.11 | 4.37 | 4.5 | 4.27 | 4.39 | 0.32 | −0.89 | −2.32 | 1.33 | 1.12 |
| OPM % | 15.81% | 13.65% | 11.81% | 10.22% | 11.15% | 10.92% | 9.74% | 9.76% | 0.71% | −1.94% | −6.15% | 2.28% | 2.3% |
| Other Income | 0.17 | 0.35 | 0.5 | 0.92 | 0.18 | 0.11 | 0.11 | 0.3 | 0.36 | 0.16 | 0.45 | 0.76 | 2.35 |
| Interest | 1.33 | 1.16 | 1.24 | 1.4 | 1.49 | 1.65 | 1.54 | 1.64 | 2.53 | 2.68 | 2.85 | 2.89 | 4.97 |
| Depreciation | 2.11 | 2.17 | 2.19 | 2.2 | 2.28 | 2.35 | 2.33 | 2.16 | 4.21 | 4.29 | 4.36 | 4.28 | 4.33 |
| PBT | 2.69 | 2.14 | 1.79 | 1.43 | 0.78 | 0.61 | 0.51 | 0.89 | −6.06 | −7.7 | −9.08 | −5.08 | −5.83 |
| Tax % | 32.34% | 27.1% | 32.96% | 32.17% | 21.79% | 201.64% | 78.43% | 41.57% | −8.09% | −9.09% | −21.7% | −1.97% | −1.54% |
| Net Profit | 1.82 | 1.56 | 1.21 | 0.97 | 0.6 | −0.61 | 0.11 | 0.52 | −5.58 | −6.99 | −7.12 | −4.98 | −5.74 |
| EPS (₹) | 1.96 | 1.68 | 1.3 | 1.04 | 0.64 | −0.6 | 0.11 | 0.35 | −5.4 | −6.76 | −4.77 | −3.32 | −3.82 |
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 60 | 62 | 80 | 135 | 170 | 155 | 169 | 187 | 191 |
| Expenses | 49 | 55 | 56 | 68 | 110 | 135 | 135 | 151 | 188 | 191 |
| Operating Profit | 6 | 5 | 5 | 11 | 26 | 35 | 20 | 18 | −1 | −1 |
| OPM % | 10% | 8% | 9% | 14% | 19% | 21% | 13% | 10% | −0.5% | −0.4% |
| Other Income | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 4 |
| Interest | 0 | 1 | 1 | 1 | 2 | 4 | 5 | 7 | 12 | 13 |
| Depreciation | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 9 | 17 | 17 |
| PBT | 2 | 2 | 1 | 9 | 19 | 25 | 8 | 3 | −28 | −28 |
| Tax % | 34% | 7% | 38% | 24% | 28% | 26% | 31% | 78% | −12% | — |
| Net Profit | 1 | 2 | 1 | 7 | 14 | 18 | 6 | 1 | −25 | −25 |
| EPS (₹) | 1.19 | 2.06 | 0.92 | 7.43 | 14.96 | 20.02 | 5.95 | 0.42 | −16.44 | −18.67 |
| Div. Payout % | 56% | 32% | 43% | 9% | 5% | 5% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 7 | 9 | 9 | 10 | 10 |
| Reserves | 48 | 49 | 49 | 56 | 76 | 114 | 194 | 176 | 165 |
| Borrowings | 0 | 5 | 6 | 10 | 53 | 97 | 109 | 152 | 162 |
| Other Liabilities | 19 | 14 | 14 | 27 | 29 | 70 | 64 | 81 | 87 |
| Total Liabilities | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 424 |
| Fixed Assets | 22 | 24 | 24 | 38 | 66 | 97 | 103 | 284 | 274 |
| CWIP | 1 | 2 | 2 | 7 | 20 | 88 | 144 | 0 | 4 |
| Investments | 5 | 5 | 6 | 0 | 0 | 0 | 3 | 3 | 3 |
| Other Assets | 45 | 43 | 45 | 54 | 79 | 105 | 127 | 133 | 143 |
| Total Assets | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 424 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 5 | 2 | 7 | 13 | −1 | 17 | −8 | 27 | 11 |
| Investing | −1 | −7 | −6 | −16 | −46 | −105 | −73 | −44 | −11 |
| Financing | −4 | 4 | −1 | 3 | 48 | 87 | 82 | 16 | −1 |
| Net Cash Flow | 0 | −1 | 0 | 0 | 1 | 0 | 1 | −2 | 0 |
| Free Cash Flow | 4 | −5 | 2 | −11 | −47 | −88 | −79 | −18 | −1 |
| CFO/OP | 97 | 57 | 144 | 134 | 17 | 64 | −32 | 162 | −1,634 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 208 | 197 | 180 | 123 | 71 | 112 | 128 | 134 | 139 |
| Inventory Days | 149 | 87 | 89 | 82 | 34 | 45 | 88 | 109 | 94 |
| Days Payable | 185 | 114 | 91 | 159 | 98 | 127 | 141 | 166 | 197 |
| Cash Conversion Cycle | 172 | 170 | 179 | 45 | 7 | 30 | 75 | 78 | 36 |
| Working Capital Days | 186 | 143 | 121 | 35 | 73 | 61 | 80 | 53 | −1 |
| ROCE % | — | 5% | 4% | 11% | 21% | 15% | 5% | 3% | −5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Natural Capsules insights
70 extracted metrics across FY08–FY27.
Documents
- Q1 FY27 concall · Aug 2026PPT
- Q4 FY26 concall · Jun 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Feb 2026PPT
- Q2 FY26 concall · Nov 2025Transcript PPT
- 19 Mar 2026
- 13 Aug 2025
- 26 Nov 2024
- 4 Oct 2023
- 13 Sep 2023
- General announcements 9 Oct 2026
Frequently Asked Questions about Natural Capsules
What does Natural Capsules Ltd do?
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives
Where is Natural Capsules Ltd (NATCAPSUQ) listed?
Natural Capsules Ltd trades as NATCAPSUQ on the NSE and under code 524654 on the BSE.
Which sector does Natural Capsules Ltd belong to?
Natural Capsules Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Natural Capsules Ltd?
Over the last 52 weeks Natural Capsules Ltd has traded between ₹131.16 and ₹234 as of 4 Nov 2026.
Does Natural Capsules Ltd pay dividends?
Natural Capsules Ltd has a dividend yield of 0.74%.
What is the Return on Equity (ROE) of Natural Capsules Ltd?
Natural Capsules Ltd reported a return on equity of -9.45%. Its debt-to-equity ratio is 0.93.
Company Information
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives
Website naturalcapsules.com
CEO Mr. Sunil Laxminarayana Kumar Mundra
Employees 619
Listed 14 Feb 2025
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NATCAPSUQ.md for Natural Capsules Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.